Logo for LaunchBio Program: Larger than Life ScienceLogo for LaunchBio Program: Larger than Life Science

Building a Strong Network for Life Science Innovators



Navigating the Path to Financing


5:30 – 6:30PM: Registration, Networking & Refreshments/Snacks

6:15 – 6:30PM: Tour of BioLabs

6:30 – 7:30PM: Panel Discussion

7:30 – 8:00PM: Networking & Drinks

Panel 1

The path to funding is never easy for an early-stage life science company. The 2023 outlook on investments indicates that venture capitalists will continue to have a high bar for investing in new companies. So, when you gain traction from potential investors, having your ducks in a row is critical to setting yourself up for a successful engagement. Understanding which key milestones investors seek can help you know when to engage and how to prepare in advance. Additionally, understanding which audited financial statements and GAAP accounting records are needed will prevent delays in the due diligence process. Implementing these practices early on can help you with your current round of funding and be prepared for future rounds by knowing how much you need to get there and identifying issues that could create problems later on.

Learn from investors on what sets companies apart in 2023 and from audit professionals on how to put your best foot forward when seeking funding.


  • Adam Jenkins, PhD, MBA, Regional Site Director, BioLabs

    Adam Jenkins, PhD, MBA, Regional Site Director, BioLabs

    Adam is currently the regional site director for BioLabs, where he manages sites across Boston, Cambridge, and Watertown. BioLabs is a global network of shared lab facilities for high-potential life-science start-ups located in key biotech clusters. Prior to BioLabs Adam worked at Biogen, a global biotech focused on neurology, where he headed their data science teams and helped lead their portfolio strategy. He holds a PhD in genetics from Boston College and an MBA from Indiana University.

  • Spring Behrouz, PhD, CEO, Vincere Biosciences

    Spring Behrouz, PhD, CEO, Vincere Biosciences

    Spring Behrouz is a translational neuroscientist dedicated to the development of therapeutics for age-related diseases. She is the founding CEO at Vincere Biosciences with a focus on modulating mitochondrial quality control mechanisms to improve age-related decline. She is also the co-founder of Vincere’s sister company, which focuses on computational tools to accelerate drug discovery. Previously she worked with Matt Farrer at Mayo clinic to characterize genetic models of Parkinson’s disease and was part of the team that discovered a new pathogenic mutation in VPS35. She is a recipient of JBJ’s 40 under 40 award, winner of several pharma and NIH scientific awards.

  • Maurizio Fazio, Senior Associate, Atlas Ventures

    Maurizio Fazio PhD, Senior Associate, Atlas Ventures

    Maurizio Fazio is a senior associate at Atlas Venture where he focuses on building companies that transform patient care by translating innovative science and technologies into novel therapeutics. Prior to joining Atlas, Maurizio completed his PhD in biological and biomedical sciences at Harvard University. His doctoral work in the lab of Dr. Leonard Zon focused on identifying genetic and epigenetic drivers of melanoma progression towards metastasis and drug resistance. While in graduate school, Maurizio was a fellow at Vida Ventures and Flagship Pioneering, and served as HILT Education Innovation Fellow mentoring student-led startups from Harvard & MIT.

  • Jeff Seremak, Partner, Deloitte & Touche LLP

    Jeff Seremak, Partner, Deloitte & Touche LLP

    Jeff is a partner at Deloitte in the Carolinas practice serving public companies, venture capital backed companies, and portfolio companies of private equity firms in the technology, life sciences, and retail industries. He has a passion for, and spends significant time, serving clients in both an audit and advisory role. Jeff leads the technology and life science industry group in Charlotte, NC and serves as a revenue recognition and lease accounting subject matter expert. He spent two years in a global national office role in London, UK leading multiple efforts including multi-billion dollar cross-border acquisitions, IPOs, debt offerings, regulatory and accounting matters, and strategic business planning.